Laser chemotherapy of human carcinoma cells with three new anticancer drugs

Adrien Eshraghi, D. J. Castro, M. B. Paiva, I. P. Grabber, N. Jongewaard, S. Arshadnia, G. Lamas, J. Soudant, R. E. Saxton

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A new experimental therapy for squamous carcinoma was tested by sensitizing human tumor cells with light-sensitive anticancer drugs followed by laser illumination at visible or infrared wavelengths. The anthrapyrazole DUP-941 and the isoquinoline derivative DUP-840 were compared with the dianthraquinone hypericin. P3 human squamous carcinoma cells were incubated for 2 h with the drugs at escalating doses ranging from 5 to 100 μg/ml, then exposed to visible green 532-nm or infrared 1064-nm light at 300 J output from a KTP/Nd:YAG laser. Tumor cell toxicity measured by in vitro MTT viability assays was minimal after DUP-840 uptake but was slightly enhanced by infrared laser emissions. By contrast, the strong tumoricidal effects seen after DUP-941 uptake were amplified over 10-fold by 532-nm light and up to 2- fold by 1064-nm light. Hypericin-sensitized tumor cells were killed after 532 nm irradiation even at the lowest drag dose but were not affected by 1064-nm illumination. The results suggest that laser chemotherapy with drugs sensitive to photothermal energy could become a useful new treatment modality for cancer.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalJournal of Clinical Laser Medicine and Surgery
Volume15
Issue number1
StatePublished - Feb 1 1997
Externally publishedYes

Fingerprint

losoxantrone
Chemotherapy
Lasers
Cells
Carcinoma
Light
Tumors
Drug Therapy
Lighting
Pharmaceutical Preparations
Squamous Cell Carcinoma
Neoplasms
Infrared radiation
Investigational Therapies
Infrared lasers
Solid-State Lasers
Dosimetry
Drag
Toxicity
Assays

ASJC Scopus subject areas

  • Biomedical Engineering
  • Surgery

Cite this

Eshraghi, A., Castro, D. J., Paiva, M. B., Grabber, I. P., Jongewaard, N., Arshadnia, S., ... Saxton, R. E. (1997). Laser chemotherapy of human carcinoma cells with three new anticancer drugs. Journal of Clinical Laser Medicine and Surgery, 15(1), 15-21.

Laser chemotherapy of human carcinoma cells with three new anticancer drugs. / Eshraghi, Adrien; Castro, D. J.; Paiva, M. B.; Grabber, I. P.; Jongewaard, N.; Arshadnia, S.; Lamas, G.; Soudant, J.; Saxton, R. E.

In: Journal of Clinical Laser Medicine and Surgery, Vol. 15, No. 1, 01.02.1997, p. 15-21.

Research output: Contribution to journalArticle

Eshraghi, A, Castro, DJ, Paiva, MB, Grabber, IP, Jongewaard, N, Arshadnia, S, Lamas, G, Soudant, J & Saxton, RE 1997, 'Laser chemotherapy of human carcinoma cells with three new anticancer drugs', Journal of Clinical Laser Medicine and Surgery, vol. 15, no. 1, pp. 15-21.
Eshraghi A, Castro DJ, Paiva MB, Grabber IP, Jongewaard N, Arshadnia S et al. Laser chemotherapy of human carcinoma cells with three new anticancer drugs. Journal of Clinical Laser Medicine and Surgery. 1997 Feb 1;15(1):15-21.
Eshraghi, Adrien ; Castro, D. J. ; Paiva, M. B. ; Grabber, I. P. ; Jongewaard, N. ; Arshadnia, S. ; Lamas, G. ; Soudant, J. ; Saxton, R. E. / Laser chemotherapy of human carcinoma cells with three new anticancer drugs. In: Journal of Clinical Laser Medicine and Surgery. 1997 ; Vol. 15, No. 1. pp. 15-21.
@article{7220299db26d4358a7d3d4efc1706da5,
title = "Laser chemotherapy of human carcinoma cells with three new anticancer drugs",
abstract = "A new experimental therapy for squamous carcinoma was tested by sensitizing human tumor cells with light-sensitive anticancer drugs followed by laser illumination at visible or infrared wavelengths. The anthrapyrazole DUP-941 and the isoquinoline derivative DUP-840 were compared with the dianthraquinone hypericin. P3 human squamous carcinoma cells were incubated for 2 h with the drugs at escalating doses ranging from 5 to 100 μg/ml, then exposed to visible green 532-nm or infrared 1064-nm light at 300 J output from a KTP/Nd:YAG laser. Tumor cell toxicity measured by in vitro MTT viability assays was minimal after DUP-840 uptake but was slightly enhanced by infrared laser emissions. By contrast, the strong tumoricidal effects seen after DUP-941 uptake were amplified over 10-fold by 532-nm light and up to 2- fold by 1064-nm light. Hypericin-sensitized tumor cells were killed after 532 nm irradiation even at the lowest drag dose but were not affected by 1064-nm illumination. The results suggest that laser chemotherapy with drugs sensitive to photothermal energy could become a useful new treatment modality for cancer.",
author = "Adrien Eshraghi and Castro, {D. J.} and Paiva, {M. B.} and Grabber, {I. P.} and N. Jongewaard and S. Arshadnia and G. Lamas and J. Soudant and Saxton, {R. E.}",
year = "1997",
month = "2",
day = "1",
language = "English",
volume = "15",
pages = "15--21",
journal = "Photomedicine and Laser Surgery",
issn = "1549-5418",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Laser chemotherapy of human carcinoma cells with three new anticancer drugs

AU - Eshraghi, Adrien

AU - Castro, D. J.

AU - Paiva, M. B.

AU - Grabber, I. P.

AU - Jongewaard, N.

AU - Arshadnia, S.

AU - Lamas, G.

AU - Soudant, J.

AU - Saxton, R. E.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - A new experimental therapy for squamous carcinoma was tested by sensitizing human tumor cells with light-sensitive anticancer drugs followed by laser illumination at visible or infrared wavelengths. The anthrapyrazole DUP-941 and the isoquinoline derivative DUP-840 were compared with the dianthraquinone hypericin. P3 human squamous carcinoma cells were incubated for 2 h with the drugs at escalating doses ranging from 5 to 100 μg/ml, then exposed to visible green 532-nm or infrared 1064-nm light at 300 J output from a KTP/Nd:YAG laser. Tumor cell toxicity measured by in vitro MTT viability assays was minimal after DUP-840 uptake but was slightly enhanced by infrared laser emissions. By contrast, the strong tumoricidal effects seen after DUP-941 uptake were amplified over 10-fold by 532-nm light and up to 2- fold by 1064-nm light. Hypericin-sensitized tumor cells were killed after 532 nm irradiation even at the lowest drag dose but were not affected by 1064-nm illumination. The results suggest that laser chemotherapy with drugs sensitive to photothermal energy could become a useful new treatment modality for cancer.

AB - A new experimental therapy for squamous carcinoma was tested by sensitizing human tumor cells with light-sensitive anticancer drugs followed by laser illumination at visible or infrared wavelengths. The anthrapyrazole DUP-941 and the isoquinoline derivative DUP-840 were compared with the dianthraquinone hypericin. P3 human squamous carcinoma cells were incubated for 2 h with the drugs at escalating doses ranging from 5 to 100 μg/ml, then exposed to visible green 532-nm or infrared 1064-nm light at 300 J output from a KTP/Nd:YAG laser. Tumor cell toxicity measured by in vitro MTT viability assays was minimal after DUP-840 uptake but was slightly enhanced by infrared laser emissions. By contrast, the strong tumoricidal effects seen after DUP-941 uptake were amplified over 10-fold by 532-nm light and up to 2- fold by 1064-nm light. Hypericin-sensitized tumor cells were killed after 532 nm irradiation even at the lowest drag dose but were not affected by 1064-nm illumination. The results suggest that laser chemotherapy with drugs sensitive to photothermal energy could become a useful new treatment modality for cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031080680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031080680&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 15

EP - 21

JO - Photomedicine and Laser Surgery

JF - Photomedicine and Laser Surgery

SN - 1549-5418

IS - 1

ER -